Paolo A. Ascierto

Now Published: Insights from @SITCancer experts on the surveillance and management of post-ICI delayed or chronic irAEs, including a call for an ICI RWD irAE registry. ow.ly/69oi50YwoZV @PAscierto @kgunturuMD #immunotherapy #survivorship

Why do IO combinations fail in adjuvant melanoma? Because minimal residual disease lacks immune priming. Adjuvant IO must activate immunity, not just maintain it. With @IgnacioMelero | @jitcancer jitc.bmj.com/content/13/12/…

#ESMO25 | Melanoma ad alto rischio: follow up a 9 anni del CM-238 su nivolumab in adiuvante. Il commento di Paolo A. Ascierto @PAscierto Non perdere il contributo integrale sulla Day 3 di OncoInfo da Berlino 🔜

Melanoma resecato ad alto rischio: quali i dati a 9 anni del trial CheckMate 238 in adiuvante presentati a #ESMO25? E come si ridefinisce il ruolo di nivolumab in questo setting di pazienti? Lo abbiamo chiesto a @PAscierto shorturl.at/cnk17

#ESMO25 | Melanoma ad alto rischio: follow up a 9 anni del CM-238 su nivolumab in adiuvante. Il commento di @PAscierto 👇 Non perdere il contributo integrale sulla Day 3 di OncoInfo da Berlino 🔜

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma @PAscierto @UninaIT @istitutotumori @myESMO #ESMO25 #ESMO2025 #melsm #oncology onclive.com/view/adjuvant-…

Best responses included a complete response rate of 11.7%, a partial response rate of 6.4%, and a stable disease rate of 37.2%. #ESMO25 #melsm | @myESMO @PAscierto cancernetwork.com/view/bnt111-pl…

Congrats 🎉 @PAscierto +team on the Nivolumab long-term data in Melanoma published in @NEJM during #ESMO25 ! @myESMO

Tomorrow, Dr. @PAscierto will present the final, 9-year results from CheckMate 238, a double-blind, phase 3 study of adjuvant treatment trial in resected stage IIIB–C or stage IV #melanoma. Join the session in Hall 7.1a at 14:45 CEST on Sat., Oct. 18 bit.ly/48wliPR

FIno a poco fa un cancro metastatico nel quale due terapie erano fallite era una partita chiusa. Oggi, grazie alla medicina di precisione, è ancora tutta da giocare. Bellissimo lavoro tutto italiano appena uscito su @NatureMedicine dei miei amici @curijoey e @PAscierto

Al 10° Annual Meeting di Alleanza Contro il Cancro ho avuto l’onore di moderare una sessione con le letture magistrali del Prof. @curijoey e del Prof. @PAscierto. Si è discusso di terapie agnostiche e oltre l’immunoterapia: le grandi aspettative per il futuro dell’oncologia.

Wishing Gordon Ramsay a speedy recovery after surgery for basal cell carcinoma. His reminder to “use sunscreen” is more than advice-it’s prevention. - The sun is not our enemy — UV radiation is - Sunscreens don’t cause cancer: they protect against it.

Every Sunburn Leaves a Mark - Raising Awareness on Skin Cancer Prevention - @PAscierto oncodaily.com/voices/349811 #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

The FDA said no to a new treatment for advanced melanoma. We're collecting stories to help them understand what that means for real people. Share your voice: bit.ly/4f78kJi #Melanoma #PatientVoices #FDA #AIMatMelanoma

Thanks to a request submitted @AIOM, the drug combination investigated in the NADINA trial, has been included among the treatments reimbursed by the Italian National Health Service (SSN) under Law 648/96, for use as neoadjuvant therapy in patients with melanoma.

This is Where Ideas Capable of Improving and Transforming the World Take Place - Paolo Ascierto @PAscierto oncodaily.com/blog/paolo-asc… #Cancer #CancerResearch #PremioFabula #Medicine #MedX #MedNews #MedEd #Health #Oncology #OncoDaily

🌟 Honored to receive the Campani Protagonisti 2024 award — a milestone that reflects the power of teamwork in medicine and research. Grateful to the exceptional colleagues who bring science, dedication, and humanity to our work every day. This is for all of us. 🙏

#ASCO25 | Un insight di @PAscierto sullo studio C-POST: cemiplimab in adiuvante nel paziente con #CSCC ad alto rischio. Non perdere il commento completo tra poco sul Day2 di OncoInfo! 🔜 @istitutotumori

May is Melanoma Awareness Month. Read the 7 common mistakes that put your skin at risk—and how to avoid them: 👉 corriere.it/salute/sportel… #Melanoma #Prevention #SkinHealth #FondazioneMelanoma

Introducing #SoloCoseBelle — a space to celebrate the small and meaningful moments that make life beautiful. Inspired by a personal story and the bond with #FrancoDiMare. This is just the beginning. 👉 solocosebelle.eu/solocosebelle-…